CKM Syndrome: A Hidden Cancer Threat

Individuals diagnosed with cardiovascular-kidney-metabolic (CKM) syndrome face an elevated risk of developing cancer. The risk escalates with the severity of the syndrome, ranging from a 3% increase at stage 1 to a 30% increase at stage 4.

This finding suggests that CKM staging could serve as an indicator for identifying individuals with heightened cancer risk, thereby supporting a more integrated approach to risk assessment.

While the study was observational and did not establish causality, it highlights shared pathophysiological mechanisms between CKM syndrome and cancer. These mechanisms include systemic inflammation, insulin resistance, oxidative stress, and dysfunctional adiposity.

Approximately 90% of adults in the United States are estimated to exhibit at least some components of CKM syndrome. This broad prevalence underscores the potential public health implications of the observed link.

Cancer prevention strategies are now being considered for integration into the treatment protocols for individuals with CKM syndrome. This approach aims to address the interconnected nature of these health conditions.